Literature DB >> 9709278

Reduced breast cancer mortality in women under age 50: updated results from the Malmö Mammographic Screening Program.

I Andersson1, L Janzon.   

Abstract

This article provides additional follow-up data of two cohorts from the Malmö Mammographic Screening Trial (MMST). The first cohort, MMST I, contained 7,984 women under age 50 at entry into MMST who were born between 1927 and 1932. Half were assigned to a control group and were not invited for examination until four years after the code was broken in the MMST in 1988. The second cohort, MMST II, contained 17,786 women born between 1933 and 1945. Fifty four percent of these women were randomly invited to screening between 1978 and 1990. The remaining 46%--the control group--was invited to screening between 1991 and 1994. Nine screening rounds were completed in MMST I, and a mean of five rounds were completed in MMST II; the screening interval ranged from 18 to 24 months. The effect of screening on breast cancer mortality was assessed by pooling the two cohorts. At the end of follow-up--December 1993 for MMST I and December 1995 for MMST II--there was a statistically significant 36% reduction in breast cancer mortality in the intervention groups (relative risk = 0.64; 95% CI: 0.45-0.89; P = 0.009). A harm-benefit analysis showed, however, that for every two breast cancer deaths prevented, one clinically insignificant cancer was diagnosed; for each breast cancer death prevented, 63 cancer-free women had been called back for further examinations; and for every 20 lives saved, one radiation-induced breast cancer death may have occurred. Recommendations for screening must therefore weigh mortality benefits against these negative effects.

Entities:  

Mesh:

Year:  1997        PMID: 9709278     DOI: 10.1093/jncimono/1997.22.63

Source DB:  PubMed          Journal:  J Natl Cancer Inst Monogr        ISSN: 1052-6773


  21 in total

Review 1.  Integration of breast imaging into cancer management.

Authors:  L J Esserman; D Wolverton; N Hylton
Journal:  Curr Oncol Rep       Date:  2000-11       Impact factor: 5.075

2.  Screening mammography for women aged 40-49: are we off the fence yet?

Authors:  M B Barton
Journal:  CMAJ       Date:  2001-02-20       Impact factor: 8.262

Review 3.  Preventive health care, 2001 update: screening mammography among women aged 40-49 years at average risk of breast cancer.

Authors:  J Ringash
Journal:  CMAJ       Date:  2001-02-20       Impact factor: 8.262

4.  [Bavarian mammography screening program].

Authors:  F Willgeroth; M Baumann; D Blaser; A Crispin; S Froschauer; J de Waal; S Heywang-Köbrunner; D Hölzel; V Kääb; R Rothe; V Stich; S Thomaschewski; D Walter
Journal:  Radiologe       Date:  2005-03       Impact factor: 0.635

5.  Dose reduction and its influence on diagnostic accuracy and radiation risk in digital mammography: an observer performance study using an anthropomorphic breast phantom.

Authors:  T Svahn; B Hemdal; M Ruschin; D P Chakraborty; I Andersson; A Tingberg; S Mattsson
Journal:  Br J Radiol       Date:  2007-07       Impact factor: 3.039

Review 6.  Statistical analyses in Swedish randomised trials on mammography screening and in other randomised trials on cancer screening: a systematic review.

Authors:  Philippe Autier; Mathieu Boniol; Michel Smans; Richard Sullivan; Peter Boyle
Journal:  J R Soc Med       Date:  2015-07-07       Impact factor: 5.344

7.  Evaluation of risk communication in a mammography patient decision aid.

Authors:  Krystal A Klein; Lindsey Watson; Joan S Ash; Karen B Eden
Journal:  Patient Educ Couns       Date:  2016-02-26

8.  Impact of mammography detection on the course of breast cancer in women aged 40-49 years.

Authors:  Judith A Malmgren; Jay Parikh; Mary K Atwood; Henry G Kaplan
Journal:  Radiology       Date:  2012-03       Impact factor: 11.105

Review 9.  Screening for breast cancer.

Authors:  Joann G Elmore; Katrina Armstrong; Constance D Lehman; Suzanne W Fletcher
Journal:  JAMA       Date:  2005-03-09       Impact factor: 56.272

10.  Screening mammography for women aged 40 to 49 years at average risk for breast cancer: an evidence-based analysis.

Authors: 
Journal:  Ont Health Technol Assess Ser       Date:  2007-01-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.